Strategy+ Advises Pfizer (NYSE: PFE) on Acquisition of Hospira, Inc (NYSE: HSP)

By

Strategy+ originated and advised Pfizer (NYSE: PFE) on the $17 Billion acquisition of Hospira, Inc (NYSE: HSP).

Strategy+ advised one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Hospira, Inc. (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars. The definitive merger agreement was announced February 5, 2015. Pfizer agreed to acquire Hospira for a total enterprise value of approximately $17 Billion in cash.

‍

Read the transaction press release

Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

strategyadd.com (the “Strategy Group LLC Website”) is a website operated by Strategy Group LLC, a privately held Florida limited liability company. Strategy Group LLC is not a registered broker-dealer. Strategy Group LLC provides strategic advisory and consulting services strictly in connection with mergers and acquisitions and capital raising. Strategy Group LLC does not act as a broker-dealer, does not engage in securities transactions, and does not receive transaction-based compensation. Strategy Group LLC’s services are limited to strategic advisory, and it does not perform or facilitate securities sales or trades.